Company: Corcept Therapeutics ( CORT)

Drug/indication: Corlux for Cushing's syndrome

Estimated timing: Fourth quarter

Recent stock performance: Up more than 20% for the year.

Cushing's syndrome is a rare disease in which patients suffer from high blood pressure, elevated blood sugar and/or diabetes and other symptoms because of exposure to high levels of the "stress hormone" cortisol.

Corcept enrolled 50 Cushing's patients in its pivotal, phase III study in which all patients are being treated with Corlux for 24 weeks. The primary endpoint of the study is improvement in glucose tolerance or a decrease in diastolic blood pressure relative to baseline. The active ingredient in Corlux is mifepristone, also known as the abortion drug RU-486.

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)